LOS ANGELES, Aug. 1 /PRNewswire-FirstCall/ -- China Pharma Holdings, Inc. (“China Pharma”) has retained CCG Elite to administer and execute its investor relations campaign. China Pharma is a bio-pharmaceutical company that develops, manufactures, and markets generic and brand products in China for a wide range of conditions, including infections, cardiovascular and CNS diseases, hepatitis, and Alzheimer’s disease.
“China Pharma Holding, Inc. is aggressively pursuing a strategy of growth in revenue and market share in China,” commented Li Zhi Lin, President and CEO. “Our strong performance in the first quarter of 2006 proves the strength of our business model. We will continue to grow by targeting the markets for stroke, heart attack, and hepatitis with our newly approved drugs.”
China Pharma recently received approvals from China’s State Food and Drug Administration (SFDA) to manufacture and market three new generic products that target the rapidly growing stroke and heart attack markets in China: Ozagrel, Propylgallate, and Alginic Sodium Diester. It also just launched Hepatocyte Growth-promoting Factor (pHGF), which is indicated for the adjunct treatment of hepatitis at various stages.
“China Pharma has the pipeline and infrastructure to become a leading player in the rapidly developing multi-billion dollar pharmaceutical market in China,” commented Crocker Coulson, President of CCG Elite. “Its extensive sales force and manufacturing base fuelled a 60% increase in revenue and a 53% jump in net income, and contributed to a 34% net margin in the first quarter of 2006. China Pharma’s success will help it to gain attention in the US investment community.”
About CCG Elite
CCG Elite is a joint venture between Elite Communications, based in Hong Kong, and CCG, one of the leading investor relations agencies in the U.S. CCG Elite is uniquely positioned to provide an outsourced, high-level investor relations solution that combines in-depth understanding of Asia’s corporate culture and economic scene and a direct pipeline into the leading funds and broker-dealers in the U.S. CCG Elite is a global, full-service investor relations agency with corporate headquarters in Los Angeles and offices in New York City, Irvine, CA and Hong Kong. The agency’s Asia-based clients include Haier Electronics Group, Hua Han Bio-Pharmaceutical Holdings Limited, Yantai North Andre Juice Co., Sinolink Worldwide Holdings Ltd., Panva Gas Holdings Limited, Pico Far East Holdings Ltd., Kasen International Holdings Limited, Sinotronics, Good Fellow Group Limited, Century Sunshine and Citic 21CN Company Limited. CCG Elite’s U.S.-based clients include TRW Automotive Holdings, Quality Systems, Accuride Corp., SI International, Lite-On Corp. and City Telecom Ltd. For further information, contact CCG Elite directly, or visit the Company’s Web site at www.ccgir.com.
About China Pharma Holdings, Inc.
China Pharma Holdings, Inc. develops, manufactures, and markets generic and brand bio-pharmaceutical products in China that treat a wide range of conditions, including infections, hepatitis, cardiovascular and CNS diseases, and other prevailing diseases. Helpson Bio-pharmaceutical Co., Ltd (Helpson), a specialty bio-pharmaceutical company headquartered in Haikou City, Hainan province in China, is a wholly owned subsidiary of China Pharma Holdings.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as unanticipated changes in product demand, increased competition, failure to obtain or maintain intellectual property protection, downturns in the Chinese economy, uncompetitive levels of research and development, failure to obtain regulatory approvals, and other information detailed from time to time in the Company’s filings and future filings with the United States Securities and Exchange Commission.
Contact: Crocker Coulson President CCG Elite 10960 Wilshire Boulevard, Suite 2050 Los Angeles, California 90024 310 231-8600 ext 103 323 270-8886 (cell) 323 350-2793 (cell2) crocker.coulson@ccgir.com or Donald Xu Vice President, Strategic Planning and Business Development China Pharma Holdings, Inc. P.O. Box 501350 San Diego, California, 92150 858-776-8880 dxu@chinapharmaholdings.com
CCG Elite
CONTACT: Crocker Coulson, President of CCG Elite, +1-310-231-8600 ext.103, cell +1-323-270-8886, cell +1-323-350-2793, crocker.coulson@ccgir.com;or Donald Xu, Vice President, Strategic Planning and Business Development,China Pharma Holdings, Inc., +1-858-776-8880, dxu@chinapharmaholdings.com
Web site: http://www.ccgir.com/
